Medical Devices, Drug Coatings And Methods For Maintaining The Drug Coatings Thereon
Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In particular, disclosed herein is a drug delivery device comprising a balloon-expandable intraluminal stent, and a pharmaceutical agent-containing coating, wherein the coating comprises a biocompatible polyfluoro copolymer that comprises about eighty-five weight percent vinylidinefluoride copolymerized with about fifteen weight percent hexafluoropropylene and a pharmaceutical agent intermixed with said polyfluoro copolymer.
1 . A drug delivery device comprising a balloon-expandable intraluminal stent, and a pharmaceutical agent-containing coating, said coating comprising a biocompatible polyfluoro copolymer that comprises about eighty-five weight percent vinylidinefluoride copolymerized with about fifteen weight percent hexafluoropropylene and a pharmaceutical agent intermixed with said polyfluoro copolymer.
2 . The drug delivery device according to claim 1 further comprising at least one additional polymer layer.
3 . The drug delivery device according to claim 2 wherein said layer is disposed between said stent and said coating.
4 . The drug delivery device according to claim 2 wherein said layer overlays said coating.
5 . The device according to claim 1 , wherein said pharmaceutical agent is an immunosuppressive.
6 . The device according to claim 1 , wherein said pharmaceutical agent is a mTOR inhibitor.
7 . The drug delivery device according to claim 1 wherein said pharmaceutical agent is rapamycin or a macrocyclic triene analog thereof that binds FKBP12.
8 . The drug delivery device according to claim 7 wherein said rapamycin or macrocyclic triene analog thereof constitutes from about 0.001 weight percent to about seventy weight percent of said coating.
9 . The drug delivery device according to claim 7 that delivers said rapamycin or macrocyclic triene analog thereof at a dose of from about 0.001 μg/cm 2 to 100 μg/cm 2 at any of hours 1 to about 2000 following intraluminal implantation.
10 . The drug delivery device according to claim 7 that delivers said rapamycin or macrocyclic triene analog thereof at a dose of from about 0.001 μg/cm 2 to 100 μg/cm 2 at any of hours 2 to about 800 following intraluminal implantation.
11 . The drug delivery device according to any one of the preceding claims wherein said rapamycin or macrocyclic triene analog thereof is a macrocyclic triene analog of rapamycin that binds FKBP12.
12 . A method for inhibiting neointimal hyperplasia in a human comprising implanting intraluminally in said human a drug delivery device according to any one of claims 1 to 10 .
13 . The method according to claim 12 , wherein said pharmaceutical agent is a macrocyclic triene analog of rapamycin that binds FKBP12.